Skip to main content
Salarius Pharmaceuticals, Inc. logo

Salarius Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SLRX ISIN · US79400X4043 LEI · 549300CLUMLZXIHU7X22 US Professional, scientific and technical activities
Open in API
Filings indexed 702 across all filing types
Latest filing 2015-01-22 Regulatory Filings
Country US United States of America
Listing US SLRX

About Salarius Pharmaceuticals, Inc.

https://salariuspharma.com/

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for cancer patients with high unmet medical needs. The company's core technology focuses on correcting the dysregulated gene expression of cancer cells, a key driver of disease development. Its pipeline includes two classes of drugs: targeted protein inhibitors (TPIs) and targeted protein degraders (TPDs). The lead TPI candidate, seclidemstat (SP-2577), is in Phase 1/2 clinical trials, while the lead TPD candidate, SP-3164, is in IND-enabling studies. These therapeutic candidates are being developed to treat solid and hematologic cancers, including leukemias and lymphomas.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2015
Regulatory Filings Classification · 100% confidence The document is a letter from legal counsel to the SEC Division of Corporation Finance regarding a Registration Statement on Form S-1 filed by Flex Pharma, Inc. The letter discusses 'test the waters' communications under the JOBS Act related to the company's initial public offering. It references Rule 418 under the Securities Act and provides supplemental materials in response to SEC comments. The document is not a financial report, earnings release, or management discussion, but rather a regulatory correspondence related to the registration and offering process. It does not contain financial statements or detailed financial data but is a regulatory filing responding to SEC comments and providing supplemental information. Therefore, the appropriate classification is Regulatory Filings (RNS).
2015-01-22 English
S-1/A
Capital/Financing Update Classification · 100% confidence The document is identified as an Amendment No. 2 to Form S-1 Registration Statement filed with the SEC, dated January 20, 2015. It is a preliminary prospectus for an initial public offering (IPO) of common stock by Flex Pharma, Inc. The text includes details about the offering, underwriting, risk factors, use of proceeds, capitalization, management discussion and analysis, and other typical sections of an S-1 registration statement. This type of filing is a registration statement used to register securities for public offering and is not a financial report like an annual or quarterly report, nor is it an earnings release or management discussion standalone. It is also not a proxy, governance, or legal proceeding document. The S-1 registration statement is best classified under Capital/Financing Update (CAP) because it relates to the company's capital raising activities through an IPO.
2015-01-20 English
S-1/A
Capital/Financing Update Classification · 100% confidence The document is an Amendment No. 1 to Form S-1 Registration Statement filed with the SEC, dated January 13, 2015. It is a registration statement under the Securities Act of 1933 for an initial public offering (IPO) of common stock by Flex Pharma, Inc. The text includes a preliminary prospectus, details about the offering, underwriting, risk factors, and company overview. This type of filing is a registration statement related to capital raising and securities issuance, which aligns with Capital/Financing Update filings. It is not an annual report, earnings release, or any other report type. Therefore, the correct classification is Capital/Financing Update (CAP). The document length and content confirm it is a full filing, not just an announcement or certification.
2015-01-13 English
Regulatory Filings 2015
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from a company and its legal counsel to the SEC regarding comments on a confidential draft registration statement on Form S-1. It discusses stock-based compensation, valuations of common stock, and the company's IPO process. The document references the Registration Statement on Form S-1 multiple times and includes detailed explanations of accounting policies and valuations related to equity issuances. It is not the registration statement itself but a correspondence responding to SEC comments on the registration statement. Such correspondence is a regulatory filing related to the registration process but does not constitute an annual report, audit report, earnings release, or other specific report types. It is also not a report publication announcement since it contains substantive content and is not merely announcing a report's availability. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other categories.
2015-01-08 English
Regulatory Filings 2014
Regulatory Filings Classification · 100% confidence The document is a letter addressed to the U.S. Securities and Exchange Commission regarding comments on an Amendment No. 1 to a Draft Registration Statement on Form S-1 for Flex Pharma, Inc. It discusses responses to SEC staff comments on the company's registration statement, including revisions to the prospectus and risk factors. The document is not the registration statement itself but a correspondence letter responding to SEC comments on the draft registration statement. This type of document is a regulatory filing related to the registration process but does not contain financial statements or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS).
2014-12-29 English
S-1
Regulatory Filings Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC). It is a preliminary prospectus for an initial public offering (IPO) of common stock by Flex Pharma, Inc. The text includes details typical of an S-1 filing such as the registration fee calculation, underwriting information, risk factors, business overview, and financial data index. It is not an annual report, earnings release, or any other financial report but a registration statement for securities offering under the Securities Act of 1933. According to the filing definitions, this type of document is best classified under Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit into other specific categories like capital/financing update or proxy solicitation. The document length is substantial (15,000 characters), and it contains detailed information typical of an S-1 filing, not just an announcement or certification. Therefore, the appropriate classification is Regulatory Filings (RNS).
2014-12-29 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.